Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 362-369

  Saunders, Rudel A ^a   Fujii, Kazuyuki ^a,b   Alabanza, Leah ^a,c   Ravatn, Roald ^a   Kita, Tsunekazu ^d   Kudoh, Kazuya ^b   Oka, Masahiro ^e   Chin, Khew Voon ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Animal Health Diagnostic Center   (United States)

^d SAITAMA CANCER CENTER   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Camptothecin; High density lipoprotein; Hyperlipidemia; Hypertriglyceridemia; Pancreatitis; Phospholipid transfer protein; Topoisomerase I inhibitor; Topotecan

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CHOLESTEROL; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; IRINOTECAN; LIPID; LIPOPROTEIN; MELPHALAN; MITOXANTRONE; PACLITAXEL; PHOSPHOLIPID TRANSFER PROTEIN; TOPOTECAN;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG RESPONSE; EMBRYO; ENANTIOMER; GENE ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PATIENT MONITORING; PHARMACOGENETICS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; LIPIDS; MALE; MICE; MICE, INBRED C57BL; PHOSPHOLIPID TRANSFER PROTEINS; TOPOTECAN;

EID: 77953572297     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.015     Document Type: Article

References (53)

1. Chin K.V., Alabanza L., Fujii K., Kudoh K., Kita T., Kikuchi Y., et al. Application of expression genomics for predicting treatment response in cancer. Ann N Y Acad Sci 2005, 1058:186-195.
2. Raguz S., Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008, 99:387-391.
3. Alaoui-Jamali M.A., Dupre I., Qiang H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Updat 2004, 7:245-255.
4. Gottesman M.M., Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006, 580:998-1009.
5. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
6. Burnett A.K., Milligan D., Goldstone A., Prentice A., McMullin M.F., Dennis M., et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009, 145:318-332.
7. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002, 100:1224-1232.
8. Friedenberg W.R., Rue M., Blood E.A., Dalton W.S., Shustik C., Larson R.A., et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006, 106:830-838.
9. Lhomme C., Joly F., Walker J.L., Lissoni A.A., Nicoletto M.O., Manikhas G.M., et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008, 26:2674-2682.
10. Fracasso P.M., Brady M.F., Moore D.H., Walker J.L., Rose P.G., Letvak L., et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001, 19:2975-2982.
11. Carlson R.W., O'Neill A.M., Goldstein L.J., Sikic B.I., Abramson N., Stewart J.A., et al. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 2006, 24:677-681.
12. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006, 6:789-802.
13. Beretta G.L., Perego P., Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006, 13:3291-3305.
14. Groen A.K., Oude Elferink R.P., Verkade H.J., Kuipers F. The ins and outs of reverse cholesterol transport. Ann Med 2004, 36:135-145.
15. Albers J.J., Cheung M.C. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol 2004, 15:255-260.
16. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009, 10:403-411.
17. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
18. Oka M., Hitomi T., Okada T., Nakamura Si S., Nagai H., Ohba M., et al. Dual regulation of phospholipase D1 by protein kinase C alpha in vivo. Biochem Biophys Res Commun 2002, 294:1109-1113.
19. Oka M., Okada T., Nakamura S., Ohba M., Kuroki T., Kikkawa U., et al. PKCdelta inhibits PKCalpha-mediated activation of phospholipase D1 in a manner independent of its protein kinase activity. FEBS Lett 2003, 554:179-183.
20. Tu A.Y., Wolfbauer G., Albers J.J. Functional characterization of the promoter region of the human phospholipid transfer protein gene. Biochem Biophys Res Commun 1995, 217:705-711.
21. Tu A.Y., Wolfbauer G., Chen H., Albers J.J. DNA sequences essential for transcription of human phospholipid transfer protein gene in HepG2 cells. Biochem Biophys Res Commun 1997, 232:574-577.
22. Kleinveld H.A., Duif P.F., Pekelharing H.L., van Rijn H.J. Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions. Biochim Biophys Acta 1996, 1303:15-21.
23. Gatto B., Sanders M.M., Yu C., Wu H.Y., Makhey D., LaVoie E.J., et al. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 1996, 56:2795-2800.
24. Makhey D., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E.J. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 1996, 4:781-791.
25. Nishizuka Y., Kikkawa U. Early studies of protein kinase C: a historical perspective. Methods Mol Biol 2003, 233:9-18.
26. Parker P.J., Murray-Rust J. PKC at a glance. J Cell Sci 2004, 117:131-132.
27. Swannie H.C., Kaye S.B. Protein kinase C inhibitors. Curr Oncol Rep 2002, 4:37-46.
28. Ohno S., Nishizuka Y. Protein kinase C isotypes and their specific functions: prologue. J Biochem (Tokyo) 2002, 132:509-511.
29. Albers J.J., Tu A.Y., Paigen B., Chen H., Cheung M.C., Marcovina S.M. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res 1996, 26:262-267.
30. Jiang X., Francone O.L., Bruce C., Milne R., Mar J., Walsh A., et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996, 98:2373-2380.
31. Tu A.Y., Nishida H.I., Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993, 268:23098-23105.
32. Jiang X.C., Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem 1995, 270:17133-17138.
33. Tu A.Y., Paigen B., Wolfbauer G., Cheung M.C., Kennedy H., Chen H., et al. Introduction of the human PLTP transgene suppresses the atherogenic diet-induced increase in plasma phospholipid transfer activity in C57BL/6 mice. Int J Clin Lab Res 1999, 29:14-21.
34. Beamer L.J., Carroll S.F., Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997, 276:1861-1864.
35. Huuskonen J., Wohlfahrt G., Jauhiainen M., Ehnholm C., Teleman O., Olkkonen V.M. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J Lipid Res 1999, 40:1123-1130.
36. Qiu X., Mistry A., Ammirati M.J., Chrunyk B.A., Clark R.W., Cong Y., et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007, 14:106-113.
37. Jiang X.C., D'Armiento J., Mallampalli R.K., Mar J., Yan S.F., Lin M. Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia. J Biol Chem 1998, 273:15714-15718.
38. Bouly M., Masson D., Gross B., Jiang X.C., Fievet C., Castro G., et al. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem 2001, 276:25841-25847.
39. Cao G., Beyer T.P., Yang X.P., Schmidt R.J., Zhang Y., Bensch W.R., et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002, 277:39561-39565.
40. Albers J.J., Wolfbauer G., Cheung M.C., Day J.R., Ching A.F., Lok S., et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995, 1258:27-34.
41. Cappell M.S. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008, 92:889-923. ix-x.
42. Eland I.A., van Puijenbroek E.P., Sturkenboom M.J., Wilson J.H., Stricker B.H. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999, 94:2417-2422.
43. Yadav D., Pitchumoni C.S. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003, 36:54-62.
44. Jonkers I.J., Smelt A.H., Hattori H., Scheek L.M., van Gent T., de Man F.H., et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 2003, 44:1462-1469.
45. Kaser S., Laimer M., Sandhofer A., Salzmann K., Ebenbichler C.F., Patsch J.R. Effects of weight loss on PLTP activity and HDL particle size. Int J Obes Relat Metab Disord 2004, 28:1280-1282.
46. Miller J.P. Serum triglycerides, the liver and the pancreas. Curr Opin Lipidol 2000, 11:377-382.
47. Govindan R., Read W., Faust J., Mc Leod H. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer. Oncology (Huntingt) 2003, 17:27-29.
48. De Jager R., Cheverton P., Tamanoi K., Coyle J., Ducharme M., Sakamoto N., et al. DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci 2000, 922:260-273.
49. Jain S., Naithani R., Kapoor G., Nath T. l-Asparaginase induced severe hypertriglyceridemia in acute lymphoblastic leukemia with 11q23 abnormality. Leuk Res 2009, 33:e194.
50. Parsons S.K., Skapek S.X., Neufeld E.J., Kuhlman C., Young M.L., Donnelly M., et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997, 89:1886-1895.
51. Alagozlu H., Cindoruk M., Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Invest 2006, 26:297-302.
52. Wong S.F., Jakowatz J.G., Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004, 38:1655-1659.
53. Koutras A.K., Habeos I.G., Vagenakis A.G., Kalofonos H.P. Capecitabine-induced hypertriglyceridemia: a report of two cases. Anticancer Res 2006, 26:2249-2251.